|Letters to the editor|
Mewave 2018 May-Jun;18(3):e7223 doi: 10.5867/medwave.2018.03.7223
Authors response on Klebsiella pneumoniae, producer of carbapenemases
Jhosef Franck Quispe Pari, Jacqueline Olimpia Ingaruca Rojas, Abel Moises Castro Mucha, Marivel Liz Castro Ortega, Francklin Jhordy Ccoicca Hinojosa, Raul Montalvo Otivo, Alfonso Agustín Prieto Pozo, Francisco Luis Daniel Salvador Sagüez
Dear José Armando Gonzales Zamora:
We appreciate your correspondence (doi: 10.5867/medwave.2018.03.7213), related to our article published in the Journal [Quispe Pari JF, Ingaruca Rojas JO, Castro Mucha AM, Castro Ortega ML, Ccoicca Hinojosa FJ, Montalvo Otivo R, et al. Carbapenemase producing Klebsiella pneumoniae in Peru: a case report and antimicrobial resistance discussion. Medwave 2018 Mar-Abr;18(2):e7191 doi: 10.5867/medwave.2018.02.7191]. We believe that this has helped us all to reflect on the Latin American reality with regard to laboratory medicine, especially that developed in the Southern Cone.
The objective of our publication was not only to report the strain of Klebsiella pneumoniae that produces carbapenemase type KPC (Klebsiella pneumoniae Carbapenemase) but also to emphasize the principles of antimicrobial therapy and the real need to treat asymptomatic urinary tract infections, despite the fact that that the resistance phenotype tempts the physician to treat these resistant germs.
On the other hand, it is important to highlight that the local economy, both in the Huancayo region, and in all of Peru is low, making it difficult to implement equipment that allows us to perform genetic tests for the detection of resistance profiles in the centers of Health. That is why, in our Hospital, when the specimen of K. pneumoniae with phenotype of resistance to carbapenems was identified, verification was carried out with the available methodologies, which in our case consisted by the modified Hodge test and later the chromogenic method by RAPID BLUE CARBA.
In parallel, the strain was sent to the Public Health Institute of Peru, for confirmation by polymerase chain reaction (PCR), this entity sent us the report confirming the production of KPC type carbapebemases. Unfortunately, they did not send us the information about the protocols and equipment used for the confirmation of the strain in question. In any case, we have contacted the Public Health Institute to send us the same.
In short, with the confirmation of the production of carbapenemase, it was possible to take measures to contain the propagation of the strain, perform the corresponding screening and discuss the antimicrobial management of it. In addition, the current recommendations for the antimicrobial management of these resistance mechanisms were delivered in the publication, thus fulfilling one of the main objectives of the publication, especially in a world where the appearance of this type of specimens is increasing alarmingly.
From the editor
Declaration of conflicts of interest
Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.
|Address: Villaseca 21, Of. 702, Ñuñoa, Santiago de Chile.|